A Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GDC-0623 in Patients With Locally Advanced or Metastatic Solid Tumors
NCT01106599
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
61
Enrollment
INDUSTRY
Sponsor class
Conditions
Solid Cancers
Interventions
DRUG:
GDC-0623
Sponsor
Genentech, Inc.